SMi Group's 12th Annual Conference and Exhibition: Pre-Filled Syringes and Injectable Drug Devices 2020

SMi Group 15 - 16 January 2020, London, UK.
SMi are pleased to present the 12th Annual Pre-Filled Syringes and Injectable Drug Devices conference in London. As Europe's leading Pre-Filled Syringes conference, the 2020 event will assess innovations in device engineering and components, enhancement of human factors, and optimizing packaging and containment.

With the rapid expansion of the PFS market, the regulatory environment is more importance than ever. This year's programme will look at the EU MDR, Article 117 as well as insights into the MDR post-market surveillance requirements; providing a holistic review of the Pre-Filled Syringes industry.

This two-day agenda offers you peer-to-peer networking with Global Product Managers, Senior Pre-Filled Syringes Engineers, Device Testing Managers, Heads of Late-Stage Pre-Filled Syringes Development, Head of Medical Affairs, Senior Director - Combination Products & Medical Devices, Global Regulatory Affairs, Quality Assurance Manager Combination Products, Senior Pharmaceutical Assessor and many more.

Benefits of attending

  • Learn about the technological innovations that are revolutionizing the injectable drug delivery space through novel device design
  • Debate how can we prepare for the regulatory impact of Brexit and the EU MDR on devices
  • Hear industry experts uncovering the latest advancements optimizing drug biologics to improve PFS delivery
  • Assess industry case studies exploring how to overcome challenges of extractables and leachables

Chairs for 2019

  • James Mellman, Device Manager, Novartis
  • Anil Busimi, Strategy and Innovation Global Product Manager, SCHOTT

Featured speakers

  • Abha Raveau-Violette, Device Manager, AstraZeneca
  • Amanda Matthews, Senior Director, Pfizer
  • Anil-Kumar Busimi, Strategy and Innovation, Senior Global Product Manager, SCHOTT
  • Benjamin Werner, Scientist, Boehringer Ingelheim Pharma GmbH & Co. KG
  • Cedric Gysel, Healthcare Solutions Manager, Johnson & Johnson
  • Cinzia Rotella, Senior Materials Scientist, Sanofi
  • Clemens Guenther, Director Nonclinical Safety Consumer Care, Bayer
  • Colin Roscoe, Principal Human Factors Scientist, Teva Pharmaceuticals
  • Hiroki Hasegawa, Researcher, Mitsubishi Gas Chemical Company, Inc
  • James Mellman, Device Manager, Novartis A G
  • Kewei Yang, Pharmaceutical Scientist, Roche
  • Khaudeja Bano, Head of Medical Devices, Abbott Molecular Inc
  • Marion Westwood, Pharmaceutical Assessor, Medicines & Healthcare products Regulatory Agency (MHRA)
  • Matthew Nicolas, Investigator, GlaxoSmithKline
  • Nicolas Eon, Senior Global Product Manager, SCHOTT
  • Olaf Lebau, Design Engineer for Medical Devices and Combination Products, Boehringer Ingelheim GmbH
  • Raphael Nudelman, Director of Chemical and Computational Toxicology, Teva Pharmaceuticals
  • Remy Vomscheid, Director, Devices Development & Technologies, IPSEN Pharmsciences
  • Torsten Kneuss, Quality Assurance Manager Combination Products, Bayer Pharma

Plus, pre-conference workshop day will be taking place on 14th January in London:

Workshop A: A Roadmap to Regulation Quality Management Systems and Technical Standards
Workshop B: Testing Requirements of Pre-Filled Syringes led by Horst Koller, CEO, HK Packaging Consulting GmbH
Workshop C: Extractables and Leachables: Considerations for PFS Platforms

For more information and to register, please visit:
http://www.pre-filled-syringes.com/wpnwl

Early-Bird Rates

  • Register by 29th November to save £100

About SMi Group

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network.

Most Popular Now

Favipiravir flu drug 'clearly effective' in treati…

According to the multiple news articles the drug favipiravir (sold under the brand name Avigan), developed by Fujifilm Toyama Chemical, had produced encouraging outcomes ...

Understanding how COVID-19 affects children vital …

Though COVID-19 so far appears to be largely sparing children, researchers are cautioning that it is critical to understand how the virus affects kids to model the pandem...

Roche initiates Phase III clinical trial of Actemr…

Roche (SIX: RO, ROG; OTCQX: RHHBY) is working with the Food & Drug Administration (FDA) to initiate a randomised, double-blind, placebo-controlled Phase III clinical tria...

Free EDC software for non-profit COVID-19 related …

Italy-based EDC provider, Nubilaria srl, offers its ACTide EDC pro-bono for European non-profit COVID-19 Coronavirus related studies. The platform is made available for t...

Novartis commits to donate up to 130 million doses…

Novartis announced its commitment to donate up to 130 million doses of generic hydroxychloroquine to support the global COVID-19 pandemic response. Hydroxychloroquine and...

AstraZeneca to donate 9 million face masks to supp…

AstraZeneca is donating nine million face masks to support healthcare workers around the world as they respond to the COVID-19 (novel coronavirus) global pandemic. AstraZ...

Vivli to launch a portal for sharing data from COV…

In a visible sign of data sharing leadership, Vivli, the Center for Clinical Research Data has committed to serving the open science community through the launch of a COV...

COVID-19: The immune system can fight back

Melbourne researchers have mapped immune responses from one of Australia's first novel coronavirus (COVID-19) patients, showing the body's ability to fight the virus and ...

CAR macrophages go beyond T cells to fight solid t…

Chimeric antigen receptor (CAR) T cell therapy has been a game-changer for blood cancers but has faced challenges in targeting solid tumors. Now researchers from the Pere...

Singapore modelling study estimates impact of phys…

A new modelling study conducted in a simulated Singapore setting has estimated that a combined approach of physical distancing [2] interventions, comprising quarantine (f...

New kind of CRISPR technology to target RNA, inclu…

CRISPR-based genetic screens have helped scientists identify genes that are key players in sickle-cell anemia, cancer immunotherapy, lung cancer metastasis, and many othe...

Roche response to COVID-19 pandemic

Roche Group (SIX: RO, ROG; OTCQX: RHHBY), provided an update on the various actions the company is taking to address the COVID-19 pandemic. On March 19, 2020, Roche co...